CytomX Therapeutics (CTMX) Cash from Financing Activities (2014 - 2026)

CytomX Therapeutics has reported Cash from Financing Activities for 13 years, with the latest figure at $234.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities changed N/A year-over-year to $234.5 million; the trailing twelve-month figure through Mar 2026 stood at $344.9 million (up 4594.24% YoY), and the FY2025 full-year result was $110.4 million, up 1368.31% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $234.5 million, up from $16.6 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $234.5 million in Q1 2026, with the low at $7000.0 in Q1 2022.
• Historically, Cash from Financing Activities has averaged $29.5 million across 5 years, with a median of $451000.0 in 2022.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 99.99% — and 2025, when it surged 1734.67%.
• CytomX Therapeutics' Cash from Financing Activities stood at $190000.0 in 2022, then grew by 28.42% to $244000.0 in 2023, then soared by 821.72% to $2.2 million in 2024, then soared by 640.02% to $16.6 million in 2025, then surged by 1308.92% to $234.5 million in 2026.
• The last three Cash from Financing Activities figures came in at $234.5 million (Q1 2026), $16.6 million (Q4 2025), and $253000.0 (Q3 2025), per Business Quant data.